Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV ‐1 and end‐stage kidney disease on chronic haemodialysis
HIV Medicine · 2025-02 · 26 (2) · 302-307
DOI: 10.1111/hiv.13721 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HIV Medicine, online erschienen am 06.10.2024. Verfasst von Joseph J Eron und 9 weiteren Autor:innen. Beteiligte Einrichtung: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Emtricitabine, Heterocyclic Compounds, 4 or More Rings, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Introduction
Treatment for people with HIV‐1 and end‐stage kidney disease (ESKD) on haemodialysis (HD) has previously required complex dose‐adjusted regimens, with limited data on the use of a single‐tablet regimen in this population. Our aim was to assess the efficacy and safety of once‐daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and to evaluate the pharmacokinetics of bictegravir (BIC) in adults with HIV‐1 and ESKD on HD.
Methods
We performed an open‐label extension (OLE) of an open‐label, multicentre, single‐group phase 3b study (NCT02600819) of adults with ESKD on HD and HIV‐1 with virological suppression. Participants switched to elvitegravir/cobicistat/F/TAF (E/C/F/TAF) 150/150/200/10 mg for 96 weeks, following which a subgroup of US participants entered an OLE phase in which they switched to B/F/TAF 50/200/25 mg for 48 weeks, returning for study visits at weeks 4 and 12, and every 12 weeks thereafter. Study assessments included virological response, safety and pharmacokinetic analysis of BIC.
Results
Ten participants entered the OLE (median age, 55 years). Virological suppression (HIV‐1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Midway Research Center, Fort Pierce, Florida, USA.
- Triple O Research Institute P.A, West Palm Beach, Florida, USA.
- Duke University Medical Center, Durham, North Carolina, USA.
- New York Medical College, Valhalla, New York, USA.
- Orlando Immunology Center, Orlando, Florida, USA.
ORCID-Profile: Joseph J Eron
Förderung
- Gilead Sciences
Zitieren
APA
Eron, J. J., Ramgopal, M., Osiyemi, O., Mckellar, M., Slim, J., DeJesus, E., Arora, P., Blair, C., Hindman, J. T., & Wilkin, A. (2025). Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV ‐1 and end‐stage kidney disease on chronic haemodialysis. HIV Medicine, 26(2), 302-307. https://doi.org/10.1111/hiv.13721
Vancouver
Eron JJ, Ramgopal M, Osiyemi O, Mckellar M, Slim J, DeJesus E, et al. Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV ‐1 and end‐stage kidney disease on chronic haemodialysis. HIV Medicine. 2025;26(2):302-307. doi:10.1111/hiv.13721
BibTeX
@article{Eron2025,
author = {Eron, Joseph J and Ramgopal, Moti and Osiyemi, Olayemi and Mckellar, Mehri and Slim, Jihad and DeJesus, Edwin and Arora, Priyanka and Blair, Christiana and Hindman, Jason T and Wilkin, Aimee},
title = {Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV ‐1 and end‐stage kidney disease on chronic haemodialysis},
journal = {HIV Medicine},
year = {2025},
volume = {26},
number = {2},
pages = {302--307},
doi = {10.1111/hiv.13721}
}
EUVIMED